Treatment with 2141-V11 led to rejection of both injected and non-injected tumors (Fig. 5e), suggesting that the CD40-targeting Ab led to a systemic and robust immune activation, extending beyond the local tumor. The gene discussed is CD40; the disease is neoplasm.